Company Overview and News
Hong Kong’s stock market rose for a fifth straight session on Wednesday on the back of Nasdaq’s surge to another all-time high and Chinese telecoms company ZTE’s agreement to get the US ban lifted, extending gains in technology shares.
CHLLF 55BC SOTGY 2382 CBQS SNPTF AACAF CICHY 0700 CICHF AACAY CCB 0939
Mainland Chinese and Hong Kong stocks closed higher on Tuesday, bolstered by the technology sector, after Apple, Amazon and Microsoft touched fresh records helping to push the Nasdaq to an all-time closing high overnight.
1336 2628 0700 SOTGY LFC 2382 SNPTF AACAY AACAF
Shares in Apple-related firms traded in Hong Kong and China climbed on Tuesday after the US tech giant soared to a record high overnight, due to strong investor reaction to a range of new software features revealed at its annual Worldwide Developer Conference
1415 SOTGY 2382 SNPTF
Hong Kong stocks plunged below the key 30,000 level on Wednesday morning for the first time in three weeks, joining a global equity sell-off after political turmoil in Italy shook financial markets across the globe and renewed US-China trade uncertainty rattled investors.
WHGRF SOTGY WHGLY 2382 SNPTF WGHPY
Overseas investors bought China stocks for 13 consecutive days through Wednesday, while mainland traders sold Hong Kong shares for five days in a row
CICHY 55BC SOTGY CBQS 2382 CICHF SNPTF AACAY CCB AACAF 0939
Hong Kong’s benchmark stock index closed lower on Wednesday for the first time in five days, with electronics component suppliers posting heavy losses, in response to a report that US President Donald Trump is likely to impose tariffs on up to US$60 billion of Chinese imports in the tech and telecom sectors.
2007 SOTGY MS 2382 SNPTF
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...